Recent Quotes
My Watchlist
Indicators
Silicon Valley 150
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Dice Therapeutics Inc (NQ: DICE )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Aug 8, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Dice Therapeutics Inc

BioMedNewsBreaks — BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Positioned Favorably with Worldwide License to Anti-IL-17 NanoAbs
Via Investor Brand Network
Exposures Product Safety
Why These 3 Large Caps Are Bucking the August Slump
The three largest S&P 500 outperformers of August are tacking on gains in a weak market, making them intriguing momentum plays to watch for the rest of 2023. 
Via MarketBeat
Topics Economy Stocks
Exposures Fossil Fuels Interest Rates US Equities
M&A Activity, Booming Sales of Anti-IL-17 Drugs Suggest Strong Upside Potential for BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV)
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
DICE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of DICE Therapeutics, Inc. - DICE
From Kahn Swick & Foti, LLC
Via Business Wire
DICE THERAPEUTICS INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of DICE Therapeutics, Inc. - DICE
From Kahn Swick & Foti, LLC
Via Business Wire
Red Hot Eli Lilly Rolls the DICE With Its Latest Biotech Takeover
The market’s initial positive reaction to the DICE Therapeutics news suggests Eli Lilly shares will continue to sizzle this summer. 
Via MarketBeat
Eli Lilly (NYSE: LLY) Acquires DICE Therapeutics (NASDAQ: DICE): A New Step in Autoimmune Disease Treatments
Via Spotlight Growth
DICE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of DICE Therapeutics, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
DICE Therapeutics to Host R&D Investor Event on Tuesday, June 20, 2023
From DICE Therapeutics, Inc.
Via GlobeNewswire
DICE Therapeutics Reports First Quarter 2023 Financial Results and Recent Highlights
From DICE Therapeutics, Inc.
Via GlobeNewswire
DICE Therapeutics to Participate in the Bank of America Securities 2023 Healthcare Conference
From DICE Therapeutics, Inc.
Via GlobeNewswire
DICE Therapeutics to Participate in the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference
From DICE Therapeutics, Inc.
Via GlobeNewswire
DICE Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights
From DICE Therapeutics, Inc.
Via GlobeNewswire
DICE Therapeutics Announces Late-Breaking Presentation at the 2023 American Academy of Dermatology (AAD) Annual Meeting
From DICE Therapeutics, Inc.
Via GlobeNewswire
DICE Therapeutics to Participate at Upcoming Investor Conferences
From DICE Therapeutics, Inc.
Via GlobeNewswire
DICE Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
From DICE Therapeutics, Inc.
Via GlobeNewswire
DICE Therapeutics Reports Third Quarter 2022 Financial Results and Recent Highlights
From DICE Therapeutics, Inc.
Via GlobeNewswire
DICE Therapeutics to Present at Upcoming Investor Conferences
From DICE Therapeutics, Inc.
Via GlobeNewswire
DICE Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
From DICE Therapeutics, Inc.
Via GlobeNewswire
DICE Announces Pricing of Upsized Public Offering of Common Stock
From DICE Therapeutics, Inc.
Via GlobeNewswire
DICE Announces Proposed Public Offering of Common Stock
From DICE Therapeutics, Inc.
Via GlobeNewswire
DICE Therapeutics Announces Positive Topline Data from Phase 1 Clinical Trial of Lead Oral IL-17 Antagonist, DC-806, for Psoriasis
From DICE Therapeutics, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.